Zentalis Pharmaceuticals (ZNTL) Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ZNTL Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeZentalis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.23 |
| 52 Week High | US$6.95 |
| 52 Week Low | US$1.13 |
| Beta | 2 |
| 1 Month Change | 58.43% |
| 3 Month Change | 76.99% |
| 1 Year Change | 235.71% |
| 3 Year Change | -83.81% |
| 5 Year Change | -92.66% |
| Change since IPO | -81.77% |
Recent News & Updates
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry
Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) shares have had a really impressive month, gaining 28% after a shaky...Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) shareholders would be excited to see that the share price has had a...Recent updates
Shareholder Returns
| ZNTL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.5% | 3.7% | 3.2% |
| 1Y | 235.7% | 41.9% | 31.0% |
Return vs Industry: ZNTL exceeded the US Biotechs industry which returned 41.9% over the past year.
Return vs Market: ZNTL exceeded the US Market which returned 31% over the past year.
Price Volatility
| ZNTL volatility | |
|---|---|
| ZNTL Average Weekly Movement | 26.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ZNTL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ZNTL's weekly volatility has increased from 18% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 106 | Julie Eastland | zentalis.com |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.
Zentalis Pharmaceuticals, Inc. Fundamentals Summary
| ZNTL fundamental statistics | |
|---|---|
| Market cap | US$296.49m |
| Earnings (TTM) | -US$137.06m |
| Revenue (TTM) | n/a |
Is ZNTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZNTL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$137.06m |
| Earnings | -US$137.06m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ZNTL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 15:34 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zentalis Pharmaceuticals, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Andrew Fein | H.C. Wainwright & Co. |
| Andres Maldonado | H.C. Wainwright & Co. |